Conference Agenda
18th Orphan Drugs & Rare Diseases Global Congress 2022
Americas - East Coast
Gain Latest Insights on:
Paradigm Global Events is again proud to present our Orphan Drugs and Rare Diseases Global Congress 2022 Americas. It’s the 18th in the series of our Flagship tri-annual Orphan Drugs & Rare Diseases event. This congress will provide you with a comprehensive overview of the critical issues shaping the future of Orphan Drugs.
The COVID-19 Pandemic has added urgency and profoundly impacted the lives of rare disease patients because they are amongst the most vulnerable to Covid-19. The community is already experiencing considerable challenges in achieving early and detailed diagnosis and having access to care and life-saving treatment, to chronic, highly complex, progressive, and severely disabling nature of their diseases, which generate specific care needs. Undoubtedly, during this crisis, the rare diseases community is experiencing unprecedented overall disruption even more…
According to reports (Fortune Business Insights), the global orphan drugs market size was valued at USD 151 billion in 2019 and is projected to reach 340.84 billion by 2027. The oncology therapy area possesses a substantially higher share in the global market as new cancer related disease emerges and series of FDA approvals will result in increased commercialisation of these drugs. The growing demand for immunomodulators will also contribute to the orphan drugs market growth. Increasing R&D initiatives and investments by prominent players and patient advocacy involvement have resulted in major pharmaceutical breakthroughs, and the development of blockbuster drugs for the treatment of several rare diseases will create opportunities and contribute exponentially to the overall market growth.
However, the coronavirus pandemic is expected to negatively impact the global market. Another critical factor restricting the orphan drugs market is the high cost associated with this drug which can significantly limit the widespread adoption of this product, especially in emerging countries.
The two-day Congress aims to bring together stakeholders to discuss strategies and best practices, innovations, technologies and concepts that can promote rare diseases product development in an interactive, thought provoking and uplifting manner, by way of a keynote presentation, plenary sessions, panel discussions, roundtables and stream sessions.
We look forward to welcoming you to the congress!
- Current Orphan Drugs landscape and implications of COVID19
- Major drivers in the global rare disease market
- Key developmental strategies carried out and Influencing factors that may affect market share to stand out in this industry
- How is FDA managing orphan drugs during the pandemic?
- Finding innovative and alternative ways in funding the development of Orphan Drugs
- Patients perspective: what really matters to rare disease patients and caregivers?
- Key authorities facilitating development and approval of diagnostic products/services
- Coming Together in Developing Orphan Drugs and Crossing Borders
- Trends and evolution of Advanced Therapy Medicinal Products
- How Can the Developer and the Patient Assist in the Evolution and Development of Orphan Drugs to make it accessible to patients in a shorter period of time?
- Strategies to improve Access and Affordability
- What Do Developers Look for When Looking for an Outsourcing Partner?
- What Do Insurance Companies Think About Orphan Drugs? Will They Make Modifications to Their Policies to Support Patients with Rare Diseases?
- Opportunity to network with Peers, potential Partners and Investors
- And much much more...
This congress is specially created for valued stakeholders in the Rare Disease community:
Presidents, Heads/Chiefs, VPs, Directors, and Managers in the area of:
- Clinical Research Organizations
- Research and Development
- Personalised Medicine
- Regenerative Medicine
- External R&D Innovation
- Innovative Medicine
- Rare and Ultra Rare Diseases
- Cell and Gene Therapy
- Translational Science
- Molecular Geneticist
- Program Management
- Patient Advocacy Groups
- Public Affairs
- Medical Affairs
- Regulatory Affairs
- Molecular Geneticist
- Program Management
- Patient Advocacy Groups
- Public Affairs
- Medical Affairs
- Regulatory Affairs
- Market Access
- Pricing and Reimbursement
- Health Economics Outcomes Research
- Commercial Development
- Investments and Funding
- Product Specialist
- Global Strategic Services
- Business Planning and Operations
- Pharmacies
- Academia
And much more…
